Real-time vaccine safety surveillance for the early detection of adverse events

Medical Care

Volumn 45, Issue 10 SUPPL. 2, 2007, Pages

  Lieu, Tracy A ^a,b   Kulldorff, Martin ^a   Davis, Robert L ^c   Lewis, Edwin M ^d   Weintraub, Eric ^c   Yih, Katherine ^a   Yin, Ruihua ^a   Brown, Jeffrey S ^a   Platt, Richard ^a  

^a HARVARD PILGRIM HEALTH CARE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d KAISER PERMANENTE   (United States)

Author keywords

Active surveillance; Drug safety; Meningococcal vaccine; Sequential analysis; Vaccine safety

Indexed keywords

MENINGOCOCCUS VACCINE;

ADOLESCENT; CASE CONTROL STUDY; CHILD; CLINICAL TRIAL; CONFERENCE PAPER; DRUG SURVEILLANCE PROGRAM; FEMALE; HEALTH MAINTENANCE ORGANIZATION; HUMAN; MALE; MULTICENTER STUDY; PROSPECTIVE STUDY; RISK; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICS; UNITED STATES;

ADOLESCENT; ADVERSE DRUG REACTION REPORTING SYSTEMS; CASE-CONTROL STUDIES; CHILD; FEMALE; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; LIKELIHOOD FUNCTIONS; MALE; MATCHED-PAIR ANALYSIS; MENINGOCOCCAL VACCINES; MODELS, STATISTICAL; PROSPECTIVE STUDIES; RISK; UNITED STATES;

EID: 34848826898     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/mlr.0b013e3180616c0a     Document Type: Article

References (18)

1. Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med. 2001;344:564-572. (Pubitemid 32167870)
2. Kramarz P, France EK, DeStefano F, et al. Population-based study of rotavirus vaccination and intussusception. Pediatr Infect Dis J. 2001;20:410-416. (Pubitemid 32294750)
3. Topol EJ. Failing the public health - rofecoxib, Merck, and the FDA. N Engl J Med. 2004;351:1707-1709. (Pubitemid 39383201)
4. Davis RL. Vaccine safety monitoring. Presented to the Advisory Committee on Immunization Practices; June 29, 2006; Atlanta, GA.
5. Centers for Disease Control and Prevention (CDC). Guillain-Barre syndrome among recipients of Menactra meningococcal conjugate vaccine - United States, June-July 2005. MMWR Morb Mortal Wkly Rep. 2005;54:1023-1025.
6. Update: Guillain-Barre syndrome among recipients of Menactra meningococcal conjugate vaccine-United States, June 2005-September 2006. MMWR Morb Mortal Wkly Rep. 2006;55:1120 -1124.
7. Davis RL, Kolczak M, Lewis E, et al. Active surveillance of vaccine safety: a system to detect early signs of adverse events. Epidemiology. 2005;16:336 -341.
8. Ball R, Braun MM, Mootrey GT. Safety data on meningococcal polysaccharide vaccine from the Vaccine Adverse Event Reporting System. Clin Infect Dis. 2001;32:1273-1280. (Pubitemid 32405898)
9. Wise RP, Salive ME, Braun MM, et al. Postlicensure safety surveillance for varicella vaccine. JAMA. 2000;284:1271-1279.
10. McVernon J, Maclennan J, Buttery J, et al. Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old children. Pediatr Infect Dis J. 2002;21:747-753.
11. MacLennan JM, Shackley F, Heath PT, et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. JAMA. 2000;283:2795-2801. (Pubitemid 30387823)
12. Rennels M, King J Jr, Ryall R, et al. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J. 2004;23:429-435. (Pubitemid 38621482)
13. Kulldorff M, Davis RL, Kolczak M, et al. A maximized sequential probability ratio test for vaccine and drug safety surveillance. Department of Ambulatory Care and Prevention Working Paper. Available upon request via www.dacp.org/faculty-Kulldorff.html.
14. Wald A. Sequential tests of statistical hypotheses. Ann Math Stat. 1945;16:117-186.
15. Abt K. Poisson sequential sampling modified towards maximal safety in adverse event monitoring. Biomed J. 1998;40:21- 41.
16. Kulldorff M. A maximized sequential probability ratio test for drug and vaccine adverse event surveillance. Presented at the Vaccine Safety Datalink Annual Meeting; May 11, 2006; Berkeley, CA.
17. Weintraub E. Generation of background rates of Guillain-Barre syndrome. Presented at the Vaccine Safety Datalink Annual Meeting; May 10, 2006; Berkeley, CA.
18. Platt R. Prompt, active, population-based identification of adverse drug reaction signals. Presented to the Centers for Education and Research on Therapeutics - Food and Drug Administration Science Forum; April 14, 2006; Washington, DC.